In 2020, OpenText surveyed 125 pharmaceutical executives to determine how familiar each respondent is with AI technologies within their industry. The survey results revealed that an interest in AI increased to 85% in 2020, up from 47% in 2018, when a previous similar survey was conducted. Approximately 75% of respondents indicated they intend to or plan on using data scientists' analytics centers of excellence. Unlike with previous OpenText surveys, respondents indicated that issues with regulation and promotional content shy rocked to the top of the least organized areas, as opposed to document management and processing of regulatory submissions, which were well-defined areas. The incorporation of AI into the pharma industry provides a number of tangible advantages. Further findings from the recent OpenText survey revealed, the percentage of companies looking at next-generation technologies dropped from 23% in 2018 to 19% in 2020.

UK citizens appear to be losing their fear of artificial intelligence (AI) technology, according to survey research by OpenText. The enterprise information management software supplier has repeated a survey it conducted in 2017 among 2,000 British consumers. While the 2017 survey revealed that a quarter of the UK consumers asked believed their job could be replaced by AI software in the next 10 years, this dropped to around one-in-five (21%) in the 2018 survey. You forgot to provide an Email Address. This email address doesn't appear to be valid.